Share on StockTwits

Hologic (NASDAQ:HOLX)‘s stock had its “buy” rating reiterated by research analysts at Needham & Company LLC in a report released on Thursday, ARN reports.

Several other analysts have also recently commented on the stock. Analysts at ISI Group raised their price target on shares of Hologic from $24.50 to $25.00 in a research note on Thursday. Separately, analysts at Jefferies Group raised their price target on shares of Hologic from $24.00 to $26.00 in a research note on Thursday. Finally, analysts at BTIG Research initiated coverage on shares of Hologic in a research note on Thursday, April 24th. They set a “buy” rating and a $26.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have assigned a buy rating to the company’s stock. Hologic currently has an average rating of “Hold” and an average price target of $22.65.

Shares of Hologic (NASDAQ:HOLX) traded up 7.98% during mid-day trading on Thursday, hitting $22.66. The stock had a trading volume of 7,087,521 shares. Hologic has a one year low of $18.46 and a one year high of $23.24. The stock’s 50-day moving average is $21.28 and its 200-day moving average is $21.77. The company’s market cap is $6.218 billion.

Hologic (NASDAQ:HOLX) last released its earnings data on Wednesday, April 30th. The company reported $0.37 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.33 by $0.04. The company had revenue of $625.00 million for the quarter, compared to the consensus estimate of $609.35 million. On average, analysts predict that Hologic will post $1.37 earnings per share for the current fiscal year.

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products to serving the healthcare needs of women.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.